A recent study has found that a synthetic progesterone drug may have a direct anticancer effect when combined with conventional anti-estrogen treatments for women with breast cancer. The research, published in Nature Cancer, suggests that this combination may not only alleviate hot flashes associated with anti-estrogen treatment but also slow tumor growth.
According to the study, megestrol acetate, a synthetic progesterone drug already used to manage hot flashes in women with breast cancer, may have a direct anticancer effect when paired with conventional anti-estrogen treatments. This finding could have significant clinical implications for women with ER-positive breast cancer.
ER-positive breast cancer accounts for approximately three-quarters of all breast cancers and is characterized by the presence of estrogen receptors on or within cells. Conventional anti-estrogen medications are often used to reduce estrogen levels, which can slow tumor growth. However, these treatments can also lead to side effects similar to menopause symptoms, including hot flashes, bone loss, and joint and muscle pain.
The PIONEER trial, led by researchers in the United Kingdom, involved 198 postmenopausal women with ER-positive breast cancer who were randomized into three groups: those receiving only letrozole, a medication that blocks estrogen; those receiving megestrol acetate (40mg) plus letrozole; and those receiving a placebo. The results showed that the combination of megestrol acetate and letrozole may have a direct anticancer effect.
"These findings could have significant clinical impact by improving treatment adherence while positively impacting tumor control," said Esha Sachdev, MD, a breast medical oncologist at the MemorialCare Todd Cancer Institute. "However, further studies will be required to substantiate these claims."
Learn more about hair transplant at Rubenhair clinic.
Get a Free Consultation
Consult with our specialists about FUE procedure, PRP therapy or hair transplant.
